{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:36:32Z","timestamp":1773815792815,"version":"3.50.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>\n                    Over the last decades, the gonadotropin-releasing hormone (GnRH) antagonist protocol has become widely used for prevention of premature luteinizing hormone surge during ovarian stimulation with exogenous gonadotropins. Literature has shown its efficacy and safety, while maintaining similar live birth rates compared to agonist protocols. Clinicians occasionally notice a drop in serum estradiol levels after GnRH antagonist initiation. This study aimed to analyze the impact of a drop in serum estradiol levels after the administration of a GnRH antagonist on clinical outcomes in\n                    <jats:italic>in vitro<\/jats:italic>\n                    fertilization (IVF)\/intracytoplasmic sperm injection (ICSI) cycles. The results showed that estradiol drop was related to lower ongoing pregnancy, live birth and cumulative live birth rates. Estradiol drop was less frequent in cycles using gonadotropins containing luteinizing hormone (LH) activity and cycles with a drop showed a larger decrease in serum LH after the first GnRH antagonist administration, resulting in lower serum values on the day of ovulation triggering. These findings suggest that future prospective research could focus on potential optimization of luteinizing hormone (LH) levels and this study might also add to the discussion that estradiol monitoring could be useful in detecting cycles with an increased risk of less favorable outcomes.\n                  <\/jats:p>","DOI":"10.3389\/fendo.2026.1722379","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:39:37Z","timestamp":1773812377000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A drop in serum estradiol levels during GnRH antagonist cotreatment in cycles stimulated with gonadotropins is associated with lower cumulative live birth rates"],"prefix":"10.3389","volume":"17","author":[{"given":"Lara","family":"Janssens","sequence":"first","affiliation":[{"name":"Department Center for Reproductive Medicine, Antwerp University Hospital","place":["Edegem, Belgium"]},{"name":"Faculty of Medicine and Health Sciences, University of Antwerp","place":["Brussel, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ella","family":"Roelant","sequence":"additional","affiliation":[{"name":"Clinical Trial Center (CTC), CRC Antwerp, Antwerp University Hospital, University of Antwerp","place":["Edegem, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Blockeel","sequence":"additional","affiliation":[{"name":"Brussels IVF, Centre for Reproductive Medicine, Brussels University Hospital","place":["Brussel, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"De Neubourg","sequence":"additional","affiliation":[{"name":"Department Center for Reproductive Medicine, Antwerp University Hospital","place":["Edegem, Belgium"]},{"name":"Faculty of Medicine and Health Sciences, University of Antwerp","place":["Brussel, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"B1","first-page":"1990","volume-title":"Infertility prevalence estimates","year":"2023"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2024.07.009","article-title":"International Committee for Monitoring Assisted Reproductive Technology world report: assisted reproductive technology, 2015 and 2016","volume":"122","author":"Kupka","year":"2024","journal-title":"Fertil steril"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2021.06.038","article-title":"Ovarian stimulation protocols: Don\u2019t immediately change a losing team","volume":"116","author":"Quaas","year":"2021","journal-title":"Fertil Steril"},{"key":"B4","volume-title":"ESHRE guideline: ovarian stimulation for IVF\/ICSI","year":"2020"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2023.25","article-title":"Live birth rate of gonadotropin-releasing hormone antagonist versus luteal phase gonadotropin-releasing hormone agonist protocol in IVF\/ICSI: a systematic review and meta-analysis","volume":"26","author":"Liu","year":"2023","journal-title":"Expert Rev Mol Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001750.pub4","article-title":"Gonadotrophin-releasing hormone antagonists for assisted reproductive technology","volume":"4","author":"Al-Inany","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmx017","article-title":"GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type","volume":"23","author":"Lambalk","year":"2017","journal-title":"Hum Reprod Upd"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2019.09.021","article-title":"The importance of estradiol measurement in patients undergoing in vitro fertilization","volume":"501","author":"Garnett","year":"2020","journal-title":"Clin Chim Acta"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2009.02.066","article-title":"Serum estradiol levels during controlled ovarian hyperstimulation influence the pregnancy outcome of in vitro fertilization in a concentration-dependent manner","volume":"93","author":"Joo","year":"2010","journal-title":"Fertil Steril"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deh473","article-title":"Association of estradiol levels on the day of hCG administration and pregnancy achievement in IVF: a systematic review","volume":"19","author":"Kosmas","year":"2004","journal-title":"Hum Reprod"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2007.10.021","article-title":"Estradiol supplementation during the luteal phase of IVF-ICSI patients: a randomized, controlled trial","volume":"90","author":"Serna","year":"2008","journal-title":"Fertil Steril"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmac040","article-title":"What is the optimal GnRH antagonist protocol for ovarian stimulation during ART treatment? A systematic review and network meta-analysis","volume":"29","author":"Venetis","year":"2023","journal-title":"Hum Reprod Upd"},{"key":"B13","volume-title":"Speroff\u2019s clinical gynecologic endocrinology and infertility","author":"Taylor","year":"2019"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deh357","article-title":"Dose-finding study of daily gonadotropin-releasing hormone (GnRH) antagonist for the prevention of premature luteinizing hormone surges in IVF\/ICSI patients: antide and hormone levels","volume":"19","author":"Huirne","year":"2004","journal-title":"Hum Reprod"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/13.11.3023","article-title":"A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon)","volume":"13","year":"1998","journal-title":"Hum Reprod"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2022.2116424","article-title":"The LH endocrine profile in gonadotropin-releasing hormone analogue cycles","volume":"38","author":"Janssens","year":"2022","journal-title":"Gynecol Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005289.pub3","article-title":"Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI)","volume":"2014","author":"Kwan","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"key":"B19","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.fertnstert.2017.06.005","article-title":"The international glossary on infertility and fertility care, 2017","volume":"108","author":"Zegers-Hochschild","year":"2017","journal-title":"Fertil Steril"},{"key":"B20","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/molehr\/gaaa070","article-title":"Two human menopausal gonadotrophin (hMG) preparations display different early signaling in vitro","volume":"26","author":"Casarini","year":"2020","journal-title":"Mol Hum Reprod"},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.1007\/978-81-322-1686-5_16","article-title":"The role of LH in controlled ovarian stimulation","volume-title":"Principles and practice of controlled ovarian stimulation in ART","author":"Esteves","year":"2015"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/00003081-198412000-00014","article-title":"The role of gonadotropins in the selection of the preovulatory follicle","volume":"27","author":"Zeleznik","year":"1984","journal-title":"Clin Obstetr Gynecol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1046\/j.1439-0264.1999.00200.x","article-title":"The modulation of gonadotrophic hormone action on the ovary by paracrine and autocrine factors","volume":"28","author":"Campbell","year":"1999","journal-title":"Anatomia Histol Embryol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.1.5389","article-title":"Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): a role for LH in the final stages of follicular maturation","volume":"84","author":"Sullivan","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/del284","article-title":"Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial","volume":"21","author":"Andersen","year":"2006","journal-title":"Hum Reprod"},{"key":"B26","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/humrep\/dead251","article-title":"Serum progesterone is lower in ovarian stimulation with highly purified HMG compared to recombinant FSH owing to a different regulation of follicular steroidogenesis: a randomized controlled trial","volume":"39","author":"Bosch","year":"2024","journal-title":"Hum Reprod"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2011.12.016","article-title":"A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer","volume":"97","author":"Devroey","year":"2012","journal-title":"Fertil Steril"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00114","article-title":"Efficacy of follicle-stimulating hormone (FSH) alone, FSH\u2009+\u2009Luteinizing hormone, human menopausal gonadotropin or FSH\u2009+\u2009Human chorionic gonadotropin on assisted reproductive technology outcomes in the \u201cPersonalized\u201d Medicine era: A meta-analysis","volume":"8","author":"Santi","year":"2017","journal-title":"Front Endocrinol (Laus)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.fertnstert.2024.11.005","article-title":"Luteinizing hormone\u2019s critical role in ovarian stimulation","volume":"123","author":"Toner","year":"2025","journal-title":"Fertil Steril"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2013.12.009","article-title":"Luteinizing hormone and human chorionic gonadotropin: origins of difference","volume":"383","author":"Choi","year":"2014","journal-title":"Mol Cell Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2739","article-title":"The role of luteinizing hormone\/human chorionic gonadotropin receptor-specific mRNA binding protein in regulating receptor expression in human ovarian granulosa cells","volume":"91","author":"Nair","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.humrep.a136365","article-title":"Dynamics of follicular growth in the human: A model from preliminary results","volume":"1","author":"Gougeon","year":"1986","journal-title":"Hum Reprod"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0705.2002.00787.x","article-title":"Quantitative transvaginal two- and three-dimensional sonography of the ovaries: reproducibility of antral follicle counts","volume":"20","author":"Scheffer","year":"2002","journal-title":"Ultras Obstetr Gynecol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1722379\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:39:39Z","timestamp":1773812379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1722379\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":33,"alternative-id":["10.3389\/fendo.2026.1722379"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1722379","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"article-number":"1722379"}}